RxDoctor Payments Data

Jace Nye

Nurse Practitioner · Ogden, UTNPI 1902450687

Payments from drug & device makers

$1,962in general payments, 2019–2025

Across 92 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$405
  • Boston Scientific$383
  • Pfizer$234
  • Actelion Pharmaceuticals US, Inc.$213
  • Cvrx, Inc.$103
  • Johnson & Johnson$89
  • plus $535 from 14 others

What the payments were for

  • Food & beverage$1,962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,962 in reported general payments places this provider in the 85th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$42,371
Medicare patients
328
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$187,229
XareltoRivaroxaban63$66,810
EntrestoSacubitril/Valsartan42$46,828
FarxigaDapagliflozin Propanediol24$32,203
JardianceEmpagliflozin11$8,399
Ezetimibe112$3,023
Metoprolol Succinate217$2,892
Rosuvastatin Calcium148$1,831
Ranolazine ErRanolazine21$1,646
Atorvastatin Calcium212$1,581
Isosorbide Mononitrate ErIsosorbide Mononitrate90$1,070
Carvedilol151$1,042
Nifedipine ErNifedipine15$881
Nitroglycerin70$682
Losartan Potassium95$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$234$187,229179 claims
Johnson & JohnsonXarelto$89$66,81063 claims
NovartisEntresto$405$46,82842 claims
AstraZenecaFarxiga$57$32,20324 claims
Boehringer IngelheimJardiance$54$8,39911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →